Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Dr. Kuo received his DDS from Columbia University, his MS from the Harvard/MIT Division of Health Sciences and Technology and his DMSc from Harvard University. Dr. Kuo is the President of Predicine Holdings Ltd, an international organization that is committed to providing healthcare solutions related to precision medicine, development of innovative diagnostics and therapeutics, integrating data analytics. Dr. Kuo has spent over 20 years in academia and 3 years in industry. He was formerly, Chief Operating Officer of the IES Diagnostics that was developing molecular immune diagnostics tests for use in personalized medicine focused on measuring interferons for auto-immune diseases and cancer. Prior to industry, Dr. Kuo was Assistant Professor in the Department of Developmental Biology at Harvard School of Dental Medicine and Director and founder of the Harvard Clinical and Translational Science – Laboratory for Innovative Translational Technologies at Harvard Medical School to provide the Harvard biomedical research community with early access to disruptive and enabling leading edge translational technologies, which was an integral part of the Harvard Catalyst Clinical and Translational Science Center at Harvard Medical School. Dr. Kuo has also been an active member of NIH/SBIR grant review study section for the past 7 years and a peer reviewer for the Qatar National Research Fund for the past 2 years. He sat and advised on the Public-Private-Partnership and Translational CTSA Key Function Committees at the NIH and sits on numerous Scientific Advisory Boards. Dr. Kuo is on the editorial board of several international journals and is Editor-in Chief of the Journal of Circulating Biomarkers and NanoBioMedicine, reviewer of many top-tier journals and has authored over 60 peer-reviewed manuscripts and a few book chapters. He is also founder of the Otto Heinrich Warburg Cancer Research Foundation, focused to foster, fund, and realize biomedical scientific research aimed at advancing knowledge in science and discovering effective and affordable cancer treatments with a focus on cancer metabolism. Prior to leaving Harvard Medical School to industry was the recipient of the prestigious Young Mentor Award.
Oncology, precision medicine, diagnostics, liquid biopsy, therapeutics, big data, translational technologies